Story of a cancer fighter: a case of carcinoma larynx with synchronous carcinoma bladder


  • Ali Asgar Chowdhury Department of Radiotherapy, Chittagong Medical College Hospital, Chittagong, Bangladesh



Cancer, Malignant, Recurrence, Chemotherapy, Radiotherapy, Immunotherapy


Cancer is a leading cause of death globally, and even in cases where the cancer patient stays alive, a normal lifestyle is rarely possible for them. This is even more true for cases of recurrent cancer, where the patients have to go through severe mental pressure from facing possible death multiple times. Various treatment methods are still being discovered and tried for the treatment of recurrent cancer, so that patients can lead a normal life without the fear of recurrence of cancer looming over their head. The present study was conducted with the report of such a case.


Metrics Loading ...


What Is Cancer? 2007. National Cancer Institute. Available at: Accessed on 15 November, 2022.

Bailar JC, 3rd, Gornik HL. Cancer undefeated. N Eng J Med. 1997336(22):1569-74.

Cancer Statistics. National Cancer Institute. 2015. Available at: Accessed on November 15, 2022).

Throat cancer (no date) Mayo Clinic. Available at: throat-cancer/symptoms-causes/syc-20366462. Accessed on 15 November, 2022.

Lv M. Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors. Medicine. 2017;96(17):e6799.

Bermejo JL, Sundquist J, Hemminki K. Sex-specific familial risks of urinary bladder cancer and associated neoplasms in Sweden. J Int Du Cancer. 2009;124(9):2166-71.

Smedby KE. Brain metastases admissions in Sweden between 1987 and 2006. Bri J Cancer. 2009;101(11):1919-24.

Volumetric Modulated Arc Therapy (VMAT). Peter MacCallum Cancer Centre. 2016. Available at: Accessed on 15 January 2023.

Shibata H, Saito S, Uppaluri R. Immunotherapy for head and neck cancer: a paradigm shift from induction chemotherapy to neoadjuvant immunotherapy. Frontiers in Oncol. 2021;3533.

Leidner R, Crittenden M, Young K, Xiao H, Wu Y, Couey MA et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J Immunotherapy Cancer. 2021;9(5).

Hollebecque A, Meyer T, Moore KN, Machiels JP, De Greve J, López-Picazo JM et al. An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. J Clin Oncol. 2017;35(15).

Uppaluri R, Zolkind P, Lin T, Nussenbaum B, Paniello R, Rich J, et al. Immunotherapy with pembrolizumab in surgically resectable head and neck squamous cell carcinoma. Clin Cancer Res. 2020;26(19):5140-52.

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, De Castro Jr G et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet. 2019;394(10212):1915-28.






Case Reports